Endobloc (Letairis)5 MG – 10 tablet

$65.35

Each Endobloc contains 5 mg Ambrisentan 10 tablets a box. Endobloc is used to treat high blood pressure in the lungs of adults.

Active Ingrediant: Ambrisentan
Generic Name: Endobloc
Manufacturer: Cipla
Strength: 5 MG
Dosage Type: Tablet
Packaging Type: Foil in Box
Contains: 10 Tabs

Inquire Us

Ambrisentan Information

What is this drug used for?

• It is used to treat high blood pressure in the lungs.

Possible side effects

Ambrisentan may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

• Headache.
• Flushing.
• Stuffy nose.
• Cough.

Some side effects can be serious. If you experience any of these symptoms, call your doctor immediately or get emergency medical treatment:

• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.
• Signs of liver problems like dark urine, feeling tired, not hungry, upset stomach or stomach pain, light-colored stools, throwing up, or yellow skin or eyes.
• Trouble breathing that is new or worse.
• Feeling very tired or weak.
• This drug may cause you to swell or keep fluid in your body. Tell your doctor if you have swelling, weight gain, or trouble breathing.

Medication Safety Issues

International issues:

Letaris, a formerly marketed Dutch brand name product for letrozole, may be confused with Letairis, a US brand name for ambrisentan.

Storage and Stability

Store at 25°C (77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F). Store in original packaging.

Adverse Reactions

Frequency not always defined.

Cardiovascular: Peripheral edema (14% to 38%), flushing (4%)
Central nervous system: Headache (34%)
Gastrointestinal: Dyspepsia (3%)
Genitourinary: Oligospermia
Hematologic & oncologic: Decreased hemoglobin (7% to 10%; dose-dependent), anemia (7%), decreased hematocrit
Respiratory: Nasal congestion (6% to 16%), cough (13%), bronchitis (4%), sinusitis (3%)

<1%, postmarketing, and/or case reports: Cardiac failure, dizziness, fatigue, fluid retention, hypersensitivity, hypotension, increased liver enzymes, nausea, vomiting, weakness